How does the Covid-19 vaccine work?

Support us and go ad-free

President Donald Trump’s administration is considering fast-tracking an experimental coronavirus (Covid-19) vaccine from the UK for use in America ahead of the presidential election, it has been reported.

Human trials of the coronavirus vaccine candidate being developed at the University of Oxford suggest it is safe and induces an immune response to Covid-19.

Early results indicate the jab could provide double protection – generating an immune response which stimulates the body to produce both an antibody and T-cell response.

But what is the US president considering, what does the vaccine do and how does it work?

– What is president Trump considering?

Read on...

Support us and go ad-free

A report in the Financial Times said he was considering bypassing normal US regulatory standards to fast-track the coronavirus vaccine being developed at the University of Oxford for use in America.

The paper said one option being explored would involve the US Food and Drug Administration awarding “emergency use authorisation” to a vaccine in October.

– Why would this be bypassing normal regulations?

The Financial Times reported that the US government’s scientific agencies have said a vaccine would need to be studied in 30,000 people to pass the threshold for authorisation.

HEALTH Coronavirus
Daily confirmed cases of Covid-19 in the UK (PA Graphics)

The Oxford vaccine is recruiting around 12,000 people for the next phase of human trials.

– What is the Oxford vaccine?

The vaccine – called ChAdOx1 nCoV-19 – uses a weakened version of a common cold virus (adenovirus) which causes infections in chimpanzees.

It has been genetically changed so it is impossible for it to grow in humans.

It is hoped the vaccine will make the body recognise and develop an immune response to the spike protein – recognisable in images of the virus – that will help stop Covid-19 from entering human cells and therefore prevent infection.

– What do the preliminary results suggest?

The results of the clinical trials, published in the Lancet last month, indicate that the vaccine candidate has triggered two responses in the immune system.

The first is that it stimulates the immune system to produce antibodies – proteins produced by the blood in response to antigens which are harmful substances that come from outside the body, such as from viruses or bacteria – and that it also causes the body to produce T-cells.

Coronavirus – Tue Jun 23, 2020
Early results suggest the vaccine triggers antibody and T-Cell responses in humans (Imperial College London/PA)

If the non-specific immune cells which respond to any invader instantly cannot tackle it, the T-cells come into play.

These cells attack the virus directly.

With questions remaining about the duration of the antibody response to Covid-19, research suggests T-cells have a more important role in offering protection against the disease.

Sarah Gilbert, professor of vaccinology at Oxford University, explained that T-cells recognise and kill cells that have been taken over by a virus and been turned into little “virus factories”.

She added: “The two systems working together are completely complementary, first of all stopping infection coming in, and if (the virus) does get past the antibodies, (T-cells) destroy the cells that the virus has taken over.”

It is not yet known whether the Oxford vaccine candidate provides long-term immunity.

– Does this mean people can start getting vaccinated against the Covid-19?


Based on their results, researchers say further clinical studies should be done with this vaccine.

The current results focus on the immune response measured in the laboratory, and further testing is needed to confirm whether the vaccine effectively protects against infection.

– How are the trials progressing?

Thousands of participants are already enrolled in the UK, with enrolment of a further 10,000 people planned as researchers test the ChAdOx1 nCoV-19 vaccine.

Trials are also taking place in South Africa and Brazil and it is hoped an effective vaccine could be ready later this year.

Coronavirus antibody test report
The UK government has already signed off on deals for 90 million doses of promising vaccines (Simon Dawson/PA)

This trial aims to assess how well people across a broad range of ages could be protected from Covid-19.

– If a successful vaccine is developed, can it be manufactured to scale?

Production of the vaccine has already been scaled up ahead of the trial to prepare as early as possible for potential future deployment.

The UK government has signed deals for 90 million doses of promising Covid-19 vaccines, with more in the pipeline.

The latest deal is for vaccines being developed by an alliance between the pharmaceutical giants BioNtech and Pfizer as well as the firm Valneva.

This is in addition to 100 million doses of a vaccine being developed by Oxford University with AstraZeneca.

Support us and go ad-free

We need your help to keep speaking the truth

Every story that you have come to us with; each injustice you have asked us to investigate; every campaign we have fought; each of your unheard voices we amplified; we do this for you. We are making a difference on your behalf.

Our fight is your fight. You’ve supported our collective struggle every time you gave us a like; and every time you shared our work across social media. Now we need you to support us with a monthly donation.

We have published nearly 2,000 articles and over 50 films in 2021. And we want to do this and more in 2022 but we don’t have enough money to go on at this pace. So, if you value our work and want us to continue then please join us and be part of The Canary family.

In return, you get:

* Advert free reading experience
* Quarterly group video call with the Editor-in-Chief
* Behind the scenes monthly e-newsletter
* 20% discount in our shop

Almost all of our spending goes to the people who make The Canary’s content. So your contribution directly supports our writers and enables us to continue to do what we do: speaking truth, powered by you. We have weathered many attempts to shut us down and silence our vital opposition to an increasingly fascist government and right-wing mainstream media.

With your help we can continue:

* Holding political and state power to account
* Advocating for the people the system marginalises
* Being a media outlet that upholds the highest standards
* Campaigning on the issues others won’t
* Putting your lives central to everything we do

We are a drop of truth in an ocean of deceit. But we can’t do this without your support. So please, can you help us continue the fight?

The Canary Support us
  • Show Comments
    1. This is one of the worst pieces of journalism I have seen in The Canary. Apparently long on medical knowledge but woefully short on critical thinking. Long on breathless hype but short any serious analysis of what is really involved in getting any new vaccine to a safe standard. Has The Canary become yet one more stenographer for the Government?

    2. 190,000,000 doses ‘loads o money’. Is the chart correct? Infections down 80% since May Day. Not sure if I’ve got a temperature but I keep seeing three monkeys. One has a mask over its eyes, another over its ears and the third has it over its mouth. Oh and now a naked man walks by seemingly admiring a non-existent suit…

    3. I didn’t get the same vibe from this piece as others have. I am probably what people would call an anti-Vaxer but unless the masses rise up and take over, then its highly likely that someone will claim to have a vaccine and make billions and mountains of cash. Let’s face it in the newest state of Yankeeland the state of UK, the nearest the masses have come to rising up in revolution was when KFC ran out of chicken !!

    Leave a Reply

    Join the conversation

    Please read our comment moderation policy here.